阿尔伯特·布尔拉
Albert Bourla
领导U.S.大型Pharmaceuticals企业运营
专业领域
Healthcare management, life sciences
核心贡献
领导U.S.大型Pharmaceuticals企业运营
Leading large-scale Pharmaceuticals operations in U.S.
最新观点
-
布拉在Q3财报中表示,公司延续强劲商业势头并上调2026年指引:减肥药项目持续推进,肿瘤、免疫与疫苗近期里程碑凸显管线潜力,未来催化剂密集;财务纪律与生产力提升正改善利润率,高价值研发进展顺利,辉瑞正迈向下一阶段的实质性增长。
Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. Financial discipline and ongoing productivity improvement are driving efficiency, and with continued progress of our high-value R&D programs, we believe we're on a pathway to the next stage of meaningful growth.
-
辉瑞CEO布尔拉在三季度电话会上称,公司商业执行出色,上市及收购产品按运营口径增长32%;财务纪律与持续的生产力提升改善了利润率,随着高价值研发项目推进,公司正迈向下一阶段的有意义增长。
"Our excellent commercial execution, including 32% operational revenue growth in the quarter for our launched and acquired products, shows the underlying strength of our business. Financial discipline and ongoing productivity improvement are driving efficiency and contributing favorably toward our margins. And, with continued progress of our high-value R&D programs, we believe we're on a pathway to the next stage of meaningful growth."
-
管理层在电话会上介绍,肥胖症业务正围绕每月给药的berobenatide加速推进,2026年计划开展10项III期研究,首个潜在批准目标为2028年。
Pfizer is accelerating its obesity franchise around monthly-dosed berobenatide, with 10 Phase 3 studies planned in 2026 and a first potential approval targeted for 2028.